The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Official Title: Randomized Clinical Study of Maintenance Therapy With Immunomodulator MGN1703 in Patients With Extensive Disease Small Cell Lung Cancer After Platinum-Based First-Line Therapy
Study ID: NCT02200081
Brief Summary: Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Medizinische Universitaet Innsbruck, Innsbruck, , Austria
Universitair Ziekenhuis Gent, Gent, , Belgium
Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden Württemberg, Germany
Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain
Name: Veerle Surmont, MD
Affiliation: University Hospital Ghent, Belgium 9000
Role: PRINCIPAL_INVESTIGATOR
Name: Georg Pall, MD
Affiliation: Medizinische Universität Innsbruck, Innere Medizin, Hämatologie und Onkologie
Role: PRINCIPAL_INVESTIGATOR